[A monoclonal antibody that reacts with an antigen on both normal and malignant prostate cells].
To study the YDPC--a monoclonal antibody that reacts with an antigen on both normal and malignant prostate cell. A murine monoclonal antibody (MAb) designated YDPC was generated by treating the primed spleen cells with leucine methyl ester (LeuOMe) following immunization of mice with prostate cancer cell line PC-3M. YDPC reacted uniformly with all adenocarcinomas of the prostate examined. It also reacted with the surface antigen on normal prostate epithelial cells and on cells from benign prostate hyperplasia. YDPC reacted with a limited number of normal tissues including renal tubules, adrenal and sweat gland. In addition, three lymph nodes metastasis and one bladder metastasis were found to be strongly positive, while four transitional cell carcinomas of the prostate negative. Preliminary experiments showed that this antibody does specifically localize to prostate cancer xenografts in nude mice. YDPC reacts with a differentiation antigen and this antigen continues to be expressed on all adenocarcinomas of the prostate. This antibody may be useful in the diagnosis of or therapy for prostate cancer.